Filovirus-like particles produced in insect cells: Immunogenicity and protection in rodents

Journal of Infectious Diseases

Volumn 196, Issue SUPPL. 2, 2007, Pages

  Warfield, Kelly L ^a   Posten, Nichole A ^a   Swenson, Dana L ^a   Olinger, Gene G ^a   Esposito, Dominic ^b   Gillette, William K ^b   Hopkins, Ralph F ^b   Costantino, Julie ^a   Panchal, Rekha G ^b   Hartley, James L ^b   Aman, M Javad ^a,c   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

^c Integrated BioTherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; GLYCOPROTEIN; NUCLEOPROTEIN; PROTEIN VP40; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACULOVIRUS; BONE MARROW CELL; CELL MATURATION; CONFERENCE PAPER; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; EBOLA VIRUS; FEMALE; FILOVIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; INSECT CELL; MARBURG VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INFECTION; VIRUS LIKE AGENT; ANIMAL; ARTICLE; C57BL MOUSE; CELL LINE; DISEASE MODEL; FILOVIRIDAE; HUMAN; IMMUNOLOGY; PHYSIOLOGY; RODENT; VIRUS HEMORRHAGIC FEVER; VIRUS REPLICATION;

ANIMALS; CELL LINE; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; FEMALE; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; MICE, INBRED C57BL; RODENTIA; VIRUS REPLICATION;

EID: 38449102538     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/520612     Document Type: Conference Paper

References (40)

1. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 2001; 75:5205-14.
2. Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. Vesicular release of Ebola virus matrix protein VP40. Virology 2001; 283:1-6.
3. Kolesnikova L, Bugany H, Klenk HD, Becker S. VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment. J Virol 2002; 76:1825-38.
4. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002; 76:4855-65.
5. Warfield KL, Swenson DL, Demmin G, Bavari S. Filovirus-like particles as vaccines and discovery tools. Expert Rev Vaccines 2005; 4:429-40.
6. Swenson DL,Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23:3033-42.
7. Watanabe S, Watanabe T, Noda T, et al. Production of novel Ebola virus-like particles from cDNAs: an alternative to Ebola virus generation by reverse genetics. J Virol 2004; 78:999-1005.
8. Swenson DL,Warfield KL, Kuehl K, et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol 2004; 40:27-31.
9. Licata JM, Johnson RF, Han Z, Harty RN. Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol 2004; 78:7344-51.
10. Kallstrom G, Warfield KL, Swenson DL, et al. Analysis of Ebola virus and VLP release using an immunocapture assay. J Virol Methods 2005; 127:1-9.
11. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003; 100:15889-94.
12. Bosio CM, Moore BD, Warfield KL, et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 2004; 326:280-7.
13. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004; 22:3495-502.
14. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196(Suppl 2):S430-7 (in this supplement).
15. + T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005; 175:1184-91.
16. Hernando E, Llamas-Saiz AL, Foces-Foces C, et al. Biochemical and physical characterization of parvovirus minute virus of mice virus-like particles. Virology 2000; 267:299-309.
17. Madore HP, Estes MK, Zarley CD, et al. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine 1999; 17:2461-71.
18. Kang CY, Luo L, Wainberg MA, Li Y. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Biol Chem 1999; 380:353-64.
19. Jiang B, Barniak V, Smith RP, et al. Synthesis of rotavirus-like particles in insect cells: comparative and quantitative analysis. Biotechnol Bioeng 1998; 60:369-74.
20. Ye L, Lin J, Sun Y, et al. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Virology 2006; 351:260-70.
21. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 1997; 239:206-16.
22. Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for Ebola virus in guinea pigs. Virus Res 2003; 92:187-93.
23. Bavari S, Bosio CM, Wiegand E, et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002; 195:593-602.
24. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251:28-37.
25. Hevey M, Negley D, Schmaljohn A. Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virology 2003; 314:350-7.
26. Moe JB, Lambert RD, Lupton HW. Plaque assay for Ebola virus. J Clin Microbiol 1981; 13:791-3.
27. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179:1109-18.
28. Bosio CM, Aman MJ, Grogan C, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003; 188:1630-8.
29. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
30. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animals Resources Commission of Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
31. Olinger GG, Bailey MA, Dye JM, et al. Protective cytotoxic T cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J Virol 2005; 79:14189-96.
32. Tomiya N, Narang S, Lee YC, Betenbaugh MJ. Comparing N-glycan processing in mammalian cell lines to native and engineered lepidopteran insect cell lines. Glycoconj J 2004; 21:343-60.
33. Betenbaugh MJ, Tomiya N, Narang S, Hsu JT, Lee YC. Biosynthesis of human-type N-glycans in heterologous systems. Curr Opin Struct Biol 2004; 14:601-6.
34. Feldmann H, Kiley MP. Classification, structure, and replication of filoviruses. Curr Top Microbiol Immunol 1999; 235:1-21.
35. Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001;75:2660-4.
36. Simmons G, Lee A, Rennekamp AJ, Fan X, Bates P, Shen H. Identification of murine T-cell epitopes in Ebola virus nucleoprotein. Virology 2004; 318:224-30.
37. Dowling W, Thompson E, Badger C, et al. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. J Virol 2007; 81:1821-37.
38. van Oers MM. Vaccines for viral and parasitic diseases produced with baculovirus vectors. Adv Virus Res 2006; 68:193-253.
39. Beck NB, Sidhu JS, Omiecinski CJ. Baculovirus vectors repress phenobarbital-mediated gene induction and stimulate cytokine expression in primary cultures of rat hepatocytes. Gene Ther 2000; 7:1274-83.
40. Gronowski AM, Hilbert DM, Sheehan KCF, Garotta G, Schreiber RD. Baculovirus stimulates antiviral effects in mammalian cells. J Virol 1999; 73:9944-51.